All Blogs
Nov 11, 2024
5 Novel CDK7 Inhibitors Pushing the Boundaries in Oncology
In the rapidly evolving field of oncology, novel CDK7 inhibitors are emerging as game-changers, challenging the status quo of cancer treatment. By specifically targeting CDK7, these innovative therapies not only halt cancer cell proliferation but also enhance the effectiveness of existing treatments. With the abili...
Read More...
Nov 08, 2024
ORLYNVAH – The First Oral Penem in the US Market: A New Era in UTI Treatment
Urinary tract infections (UTIs) are among the most prevalent bacterial infections in the US and globally. Around 60% of women will experience an uncomplicated UTI (uUTI) during their lifetime, and up to 40% of women with a history of uUTIs may face a recurrence, according to Iterum’s approval announcement. In 20...
Read More...
Nov 07, 2024
Beta Bionics Introduces iLet Bionic Pancreas with Abbott’s FreeStyle Libre 3 Integration; Merit Medical Successfully Acquires Cook Medical’s Lead Management Portfolio; Elixir Medical’s LithiX HC-IVL System Maintains Safety and Efficacy at Six-Month Mark; Philips Launches U.S. Clinical Trial with First Patient Enrolled for New Integrated Device for PAD; FDA Grants iRhythm Technologies 510(k) Clearance for Enhanced Zio AT Device; SeeMedX Submits 510(k) for Cardiac Monitoring System Aiming to Revolutionize Heart Failure Management
Beta Bionics Launched iLet Bionic Pancreas Along With Abbott’s FreeStyle Libre 3 Plus sensor On October 30, 2024, Beta Bionics, Inc., a leader in developing advanced diabetes management solutions, announced the launch of its iLet Bionic Pancreas and its integration with Abbott’s FreeStyle Libre® 3 Plus sen...
Read More...
Nov 06, 2024
6 Groundbreaking Applications of Organoids That Are Changing Healthcare
The advent of organoid technology has marked a revolutionary milestone in biomedical research and healthcare. Organoids, which are three-dimensional structures derived from stem cells that mimic the architecture and functionality of specific organs, have opened new avenues for understanding diseases, testing drugs,...
Read More...
Nov 05, 2024
Prolong’s PP-007 Fast-Tracked for Stroke; FDA Expands JYLAMVO Pediatric Approval; Corcept’s Cushing’s Drug Shows Positive Phase III Results; ESSA Halts Phase II Study of Masofaniten for Prostate Cancer; SCEMBLIX Approved for Leukemia
Prolong Pharmaceuticals Secures FDA Fast Track for PP-007 in Stroke Therapy Prolong Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company, announced that its investigational therapy, PP-007 (PEGylated carboxyhemoglobin, bovine), has been granted Fast Track designation by the FDA for the treatment of a...
Read More...
Nov 04, 2024
CDK7 Inhibitors: A Promising Class in Cancer Therapeutics
Cyclin-dependent kinase 7 (CDK7) belongs to the CDK family of serine/threonine protein kinases and plays a crucial role in regulating the cell cycle and mRNA transcription. It is often overexpressed in various cancers, making it a promising target for cancer treatment due to its involvement in both transcription an...
Read More...
Nov 01, 2024
5 Promising Pompe Disease Drugs in Early-stage Development
Imagine a disease that stealthily incapacitates the heart, liver, and skeletal muscles—slowly breaking them down due to the absence of a crucial protein. That's the story of Pompe disease, also known as glycogen storage disease type II (GSDII). Caused by a gene mutation that blocks the body’s ability to break down ...
Read More...
Oct 31, 2024
Medtronic Secures FDA Green Light for Affera™ Mapping and Ablation System Alongside Sphere-9™ Catheter; Precision Optics Gets FDA 510(k) Clearance; Abbott Launches New Clinical Trial Aimed at Enhancing Care for Advanced Heart Failure Patients; Fresenius Medical Care’s Study Confirms Efficacy of New Anemia Therapy Software in Enhancing Outcomes for Hemodialysis Patients; Inspira™ Announces New Distribution Center to Support INSPIRA™ ART100’s U.S. Introduction; WellSky Expands Home Care Offerings with Acquisition of Bonafide
Medtronic Received FDA Approval for Affera™ Mapping and Ablation System and Sphere-9™ Catheter, Pioneering Advances in Arrhythmia Treatment On October 24, 2024, Medtronic plc, a global leader in healthcare technology, announced the United States Food and Drug Administration (FDA) approval of its Affera™ Ma...
Read More...
Oct 30, 2024
7 Key Technologies Pioneering Cybersecurity in the Healthcare Sector
In today’s digital age, cybersecurity in the healthcare sector is not just an IT concern—it's a matter of life and death. As hospitals and clinics increasingly rely on interconnected devices and electronic health records, they become prime targets for cyberattacks that can compromise sensitive patient data and disr...
Read More...
Oct 29, 2024
FDA Grants Orphan Status to MDL-101 for LAMA2-CMD; Pfizer’s ABRYSVO Approved for High-Risk Adults (18-59); KIND’s AND017 Gains Orphan Designation for Sickle Cell Disease; HiberCell’s HC-7366 Fast-Tracked for AML; ORLYNVAH Approved for Uncomplicated UTIs
FDA Grants Orphan Drug Status to MDL-101 for LAMA2-CMD Treatment Modalis Therapeutics Corporation has received Orphan Drug Designation (ODD) from the FDA for MDL-101, its promising treatment for congenital muscular dystrophy type 1A (LAMA2-CMD). This designation is a significant step, aimed at fostering the deve...
Read More...